Low triiodothyronine (T3) state is associated with poor prognosis in critical acute and prolonged illness. However, the information on thyroid dysfunction and cancer is limited. The aim of our study was to evaluate the prognostic value of low T3 syndrome in chronic lymphocytic leukemia (CLL). Two hundred and fifty-eight patients with detailed thyroid hormone profile at CLL diagnosis were enrolled. Low T3 syndrome was defined by low free T3 (FT3) level accompanied by normal-to-low free tetraiodothyronine (FT4) and thyroid-stimulating hormone (TSH) levels. A propensity score-matched method was performed to balance the baseline characteristics. Multivariate Cox regression analyses screened the independent prognostic factors related to time-to-first-treatment (TTFT) and cancer-specific survival (CSS). Area under the curve (AUC) assessed the predictive accuracy of CLL-International Prognostic Index (IPI) together with low T3 syndrome. The results showed that 37 (14.34%) patients had low T3 syndrome, which was significantly associated with unfavorable TTFT and CSS in the propensity-matched cohort, and it was an independent prognostic indicator for both TTFT and CSS. Serum FT3 level was positively related to protein metabolism and anemia, and inversely related to inflammatory state. Patients with only low FT3 demonstrated better survival than those with synchronously low FT3 and FT4, while those with synchronously low FT3, FT4 and TSH had the worst clinical outcome. Low T3 syndrome together with CLL-IPI had larger AUCs compared with CLL-IPI alone in TTFT and CSS prediction. In conclusion, low T3 syndrome may be a good candidate for predicting prognosis in future clinical practice of CLL.
Low triiodothyronine (T3) syndrome, also known as euthyroid sick syndrome (ESS) or nonthyroidal illness syndrome (NTIS), is characterized by a decrease in T3, and in more severe cases also in tetraiodothyronine (T4) level, not accompanied by a usual feedback increase in thyroid-stimulating hormone (TSH). 1 Although low T3 syndrome lowers tissue energy requirement and counteracts excessive catabolism as a physiologic adaptive response, it may aggravate clinical problems distinctively associated with prolonged critical illness, such as diminished cognitive status, ileus and cholestasis, glucose intolerance and insulin resistance, anemia and deficient clearance of triglyceride. 2 Accumulating evidence has indicated that low T3 syndrome was associated with inferior clinical outcome in patients with sepsis, 3 multiple trauma, 4 myocardial infarction and heart failure, 5 cerebrovascular diseases, 6 liver cirrhosis, 7 chronic kidney disease 8 and respiratory failure. 9 With regard to malignancies, Bunevicius et al.
concluded that low T3 syndrome was correlated with poor functional and cognitive status, worse discharge outcome and shorter survival of glioma patients. 10, 11 Yasar et al. and Cengiz et al. reported low T3 syndrome as a predictor of poor prognosis in lung cancer patients, especially in patients with non-small-cell lung cancer. 12, 13 However, besides our previous work on low T3 syndrome in diffuse large B-cell lymphoma (DLBCL), 14 few studies have focused on other cancer types including lymphoproliferative diseases.
Chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in western societies, is heterogeneous in clinical course ranging from highly indolent with observation for many years, and relatively aggressive with rapid need of antileukemia therapy. Prognostic indicators influencing survival incorporate traditional (clinical and laboratorial), cytogenetic such as del(17p) and del(11q), molecular factors including immunoglobulin heavy chain variable region (IGHV) mutational status and cell surface markers of CD38 and zeta-chain associated protein kinase 70 (ZAP-70). Bahlo et al. have developed an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) based on five parameters [TP53 status, IGHV mutational status, serum b 2 -microglobulin (b 2 -MG) concentration, clinical stage and age], which can identify four risk groups: low (CLL-IPI 0 2 1), intermediate (CLL-IPI 2 2 3), high (CLL-IPI 4 2 6) and very high (CLL-IPI 7 2 10). 15 Although CLL-IPI has been widely accepted and validated by several large independent cohorts, 16, 17 it is still critical to seek some easily obtained and valuable prognostic factors which could provide accurate and comprehensive tool to predict the heterogeneous clinical course of this cancer.
To our knowledge, no previous literature has focused on CLL patients with low T3 syndrome. The aims of our study were to investigate the association between low T3 syndrome and CLL and the prognostic value of low T3 syndrome in identifying high-risk CLL patients.
Patients and Methods

Ethics, consent and permissions
This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. All aspects of the study, including measurements for serum thyroid hormone levels and other periodical clinical and laboratorial checkups were performed according to the principles of the Declaration of Helsinki (64th, 2013). Informed consent and permissions were obtained from all subjects involved in this study.
Patients
Two hundred and seventy-nine consecutive patients with newly diagnosed CLL between January 2010 and December 2016 from the First Affiliated Hospital of Nanjing Medical University were prospectively enrolled in our study at initial diagnosis of CLL. Detailed thyroid function profile was obtained for all patients recruited. Twenty-one patients were excluded for meeting the exclusion criteria: (i) with overt history of intrinsic thyroid disorders (hypothyroidism, hyperthyroidism or thyroiditis); (ii) with comorbid conditions which could directly cause low T3 syndrome including sepsis, advanced congestive heart failure, recent myocardial infarction, acute pancreatitis, severe hepatic disease, renal failure and was positive for the human immunodeficiency virus at diagnosis; (iii) received therapy with drugs known to alter thyroid function at admission, such as amiodarone, corticosteroid and dopamine; (iv) patients who died of accident or other medical conditions with no relation to CLL were excluded to analyze the prognostic value of low T3 syndrome in CLL-specific mortality. None of the patients were diagnosed with central hypothyroidism which is mostly caused by hypothalamic or pituitary diseases/conditions such as brain tumors, cranial irradiation or trauma. Diagnosis of CLL was based on criteria of the International Workshop on CLLNational Cancer Institute (IWCLL-NCI). 18 Among the eligi- What's new? Low serum levels of thyroid hormone are associated with prolonged illness and with poor prognosis in patients with certain cancer types. Relationships between thyroid hormone levels and cancer, however, remain unclear. This study shows that low triiodothyronine (T3) syndrome is independently associated with unfavorable time-to-first-treatment and cancer-specific survival in patients with chronic lymphocytic leukemia (CLL). Compared with synchronous low T3 and T4, low free T3 levels alone were associated with better survival. Poorest clinical outcome was observed in patients with reduced T3, T4 and thyroidstimulating hormone. The findings suggest that thyroid hormone levels are prognostic in CLL.
levels were accessible from the hospital-based laboratory service. Glasgow Prognostic Score (GPS) was evaluated as follows: patients with elevated CRP concentration (>1 mg/dl) in combination with hypoalbuminemia (<3.5 g/dl) were allocated 2 points; patients with elevated CRP alone or hypoalbuminemia alone were allocated 1 point, while patients within normal limits were allocated 0 point. Genomic DNA was isolated from mononuclear cells using the QIAamp DNA Blood Kits (Qiagen, D€ usseldorf, Germany) according to the manufacturer's recommendation. The mutational status of TP53 and IGHV were assessed as previously described. 21, 22 A germline homology of 98% was used as the cutoff between IGHV mutated and unmutated cases. Fluorescence in situ hybridization analysis was performed to detect the cytogenetic abnormalities of certain chromosomal regions including 11q and 17p by using the fluorescent-labeled probes LSI ATM (11q22) and LSI p53 (17p13) (Vysis, Downers Grove, IL, USA). The determination of del(11q22) and del(17p13) positivity needed >8.9% and 5% of cells, respectively. 23 We referred the cohort with TP53 mutation and/or del(17p13) as TP53 disruption. Immunophenotyping of CD38 and ZAP-70 expression were performed as described. 24, 25 Cutoff points of 30% and 20% were used to define the positivity for CD38 and ZAP-70, respectively.
The thyroid function profile was evaluated at the time of CLL diagnosis and measured in all patients via chemiluminescent immunoassay (AutoBio 12 Co., Ltd., Zhengzhou, China). According to the manufacturer's instruction, the reference intervals were 3.10-6.80 pmol/l for serum free T3 (FT3), 12.00-22.00 pmol/l for serum free T4 (FT4), 0.27-4.20 mIU/l for TSH, 1.30-3.10 nmol/l for total T3 (TT3), 66.00-181.00 nmol/l for total T4 (TT4), 3.50-77.00 ng/ml for thyroglobulin, <34.00 IU/ml for antithyroid peroxidase and <115.00 IU/ml for antithyroglobulin. Low T3 syndrome was defined by a low serum level of FT3 accompanied by normal-to-low serum FT4 and TSH levels.
Follow-up and outcome measures
The follow-up events included time-to-first-treatment (TTFT) and cancer-specific survival (CSS). TTFT refers to the period from initial diagnosis to either the time of the first CLLspecific treatment or the last follow-up date. CSS is calculated as the interval between diagnosis and CLL-specific death or the end of follow-up. Cause of death coded as C91.1 based on the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10 code) was classified as CLL-specific death. 26 Eight deaths resulting from other causes, including three pneumonia (ICD-10 code J12.9 and J15.9), two lung cancers (ICD-10 code C34.9), two ischemic heart diseases (ICD-10 code I25.9) and one stroke (ICD-10 code I64) were excluded from the analyses. The follow-up and mortality data were carefully retrieved from hospital records, death certificates in local disease control center or by interviewing (directly or by telephone) the patients, their families and personal physicians. The patients were prospectively followed for 7-92 months until August 2017, with a median follow-up time of 45 months.
Statistical analyses
Categorical variables were presented in percentage (%) and analyzed using the Pearson's v 2 test or the Fisher's exact test. Continuous variables were expressed as mean 6 standard deviation and determined as to whether they were normally distributed using the Kolmogorov-Smirnov test or the ShapiroWilk test. For data following normal distribution, results were compared by the Student's t test. While for data following nonnormal distribution, the Mann-Whitney U test or the Kruskal Wallis test was applied. Correlations were quantified by the Pearson's r or the Spearman test for parametric and nonparametric data analyses, respectively. Survival curves were calculated using the Kaplan-Meier method and differences in survival were compared using the log-rank test. Multivariate analyses were performed by Cox regression and logistic regression models, and variance inflation factor (VIF) was evaluated to rule out multicollinearity between the included parameters. Propensity score-matched (PSM) analyses, using the 1:1 nearest neighbor technique with a small caliper of 0.1 to ensure better balance, were performed to re-evaluate univariate and multivariate analyses in matched couples. Receiver-operator characteristic (ROC) curve and corresponding area under the curve (AUC) were constructed to assess the predictive accuracy of CLL-IPI together with low T3 syndrome, and the differences in AUCs were tested by a nonparametric approach developed by DeLong ER et al. 27 Statistical analyses were carried out using SPSS 23.0 (SPSS, Chicago, IL) and R software 3.2.5 (http://www.r-project.org/) with MatchIt packages. A twosided p < 0.05 was considered statistically significant.
Results
Patients' baseline characteristics according to low T3 syndrome A total of 258 CLL patients with detailed thyroid function profile entered the final analyses. Thirty-seven (14.34%) cases (22 male; mean age 64.54 6 10.71) had pre-existing low T3 syndrome which is characterized by FT3 level below 3.10 pmol/l, FT4 and TSH levels within or lower than the normal ranges at diagnosis, while the other 221 (85.66%) cases (130 male; mean age 60.39 6 12.19) did not have low T3 syndrome. The average values of serum FT3, FT4 and TSH concentrations were 2.54 6 0.55 pmol/l, 12.10 6 3.95 pmol/l and 2.11 6 1.38 mIU/l, respectively, for patients with low T3 syndrome and 4.31 6 0.69 pmol/l, 16.42 6 2.63 pmol/l and 2.58 6 1.32 mIU/l for non-low T3 syndrome. Among these 37 patients with low T3 syndrome, 20 (54.05%) were tested with synchronously decreased FT3 and FT4, while the remaining 17 (45.95%) were examined with only low FT3. Notably, concurrently declined FT3, FT4 and TSH levels were detected in 8 out of 20 (40.00%) patients mentioned above.
Demographic, clinical and biological properties of subjects with and without low T3 syndrome were depicted in Table 1 . For clinical parameters, a significant dominance was We further explored the relationship between serum FT3 and protein metabolism, anemia and inflammatory state using the Pearson's correlation analyses. Serum FT3 was positively related to albumin (r 5 0.380, p < 0.001) and anemia indicator of Hb (r 5 0.365, p < 0.001), and inversely related to inflammatory status shown by CRP (r 5 20.235, p < 0.001). GPS as an inflammation-based prognostic score was defined according to serum concentrations of albumin and CRP. Evident differences in FT3 level (GPS 0: 4.31 6 0.78 pmol/l, GPS 1: 3.89 6 0.93 pmol/l, GPS 2: 3.41 6 1.00 pmol/l; p < 0.001) and low T3 syndrome morbidity (GPS 0: 6.38%, GPS 1: 20.48%, GPS 2: 32.35%; p < 0.001) were observed among the three risk scores. Patients with GPS 2 points exhibited both lowest FT3 level and highest incidence for low T3 syndrome.
Prognostic value of low T3 syndrome in CLL
No significant difference in follow-up time was identified for patients with and without low T3 syndrome (median followup time: 47 months vs 45 months, p 5 0.308). During the median follow-up of 45 months, 192 (74.42%) patients received therapy, while the other 66 (25.58%) remained stable and were managed according to the watch-and-wait approach. In addition, 62 (24.03%) cases died, while the other 196 (75.97%) survived until the end of follow-up. As demonstrated in Figures 1a and 1b , the median TTFT for patients with low T3 syndrome was significantly shorter than those without low T3 syndrome (2 months vs 11 months, p < 0.001). A similar result was also indicated as to CSS with 51 months for low T3 syndrome, while the median survival was not reached for non-low T3 syndrome (p < 0.001).
Clinical and laboratorial variables including gender, age, Binet stage, ECOG PS, CIRS, status of low T3 syndrome, levels of Hb, PLT, LDH and b 2 -MG, together with cytogenetic and molecular parameters of TP53 disruption, ATM deletion, IGHV unmutated status, CD38 and ZAP-70 entered the univariate and multivariate Cox regression analyses (VIF < 10 for both TTFT and CSS) ( Table 2) The five significant variables are in accordance with the parameters in CLL-IPI, which to some degree validated the prognostic effectiveness and reproducibility of CLL-IPI. Accordingly, low T3 syndrome was an independent prognostic factor not only for TTFT but also for CSS.
The univariate and multivariate Cox regression analyses for CSS were also performed in 192 treated patients including the chemotherapy received (Supporting Information, Table  2 ). After adjusting for the cofounders including the treatment type (intensive and less intensive), low T3 syndrome still remained as a significant factor associated with unfavorable CSS (HR 5 2.192; 95% CI: 1.135-4.235; p 5 0.019). 3 Intensive treatments referred to fludarabine, cyclophosphamide 6 rituximab or bendamustine. 4 Less intensive treatments referred to chlorambucil 6 rituximab.
Propensity score-matched analyses
To further corroborate the results observed in the whole cohort, PSM analyses were carried out. Considering the imbalance in characteristics between patients with and without low T3 syndrome, we applied a 1:1 PSM ratio with a small caliper of 0.1 for matching the potential cofounders including sex, age, Binet stage, ECOG PS, CIRS, Hb, PLT, LDH and b 2 -MG levels, TP53 disruption, ATM deletion, IGHV unmutated status, CD38 and ZAP-70 expressions. Distribution of covariates was adequately balanced and evenly distributed in the matched dataset as shown in Table 1 (all p > 0.1). After 1:1 matching, there were 37 patients in each group. As demonstrated in the Kaplan-Meier survival curves for the matched groups (Figs. 1c and 1d) , the median TTFT was 2 months for patients with low T3 syndrome and 12 months for those without low T3 syndrome (p 5 0.009), while the median CSS was 51 months for patients with low T3 syndrome and not reached for those without low T3 syndrome (p 5 0.008). In addition, the multivariate analyses showed low T3 syndrome still remained as an independent predictor for both TTFT (HR 5 1.975; 95% CI: 1.137-3.429; p 5 0.016) and CSS (HR 5 2.793; 95% CI: 1.077-7.241; p 5 0.035) ( Table 2) .
Correlation between FT3, FT4, low T3 syndrome and short-term survival All 258 CLL patients were categorized into three subgroups according to TTFT status: 95 (36.82%) patients required immediate medication after initial diagnosis; 97 (37.60%) received treatment during the follow-up but with no indication of antileukemic therapy at CLL diagnosis; the rest 66 (25.58%) cases had no indication from beginning to end and were still under observation. As summarized in Table 3 , significant differences in serum FT3 (p < 0.001) and FT4 (p < 0.001) were identified that patients treated immediately had the lowest FT3 (3.81 6 0.94 pmol/l) and FT4 (14.21 6 2.97 pmol/l), and those without indication were examined with the highest FT3 (4.55 6 0.78 pmol/l) and FT4 (17.70 6 2.62 pmol/l). Furthermore, the incidence rate of low T3 syndrome was also evidently associated with TTFT status (p 5 0.001).
As for CSS, 196 (75.97%) cases survived. Among 62 patients who died during the entire follow-up, 17 (6.59%) deaths were recorded within 2 years from diagnosis and the other 45 (17.44%) were nonsurvivors with CSS >2 years. CLL patients who died within 2 years from diagnosis had the lowest FT3 (3.06 6 1.14 pmol/l) and FT4 (11.98 6 3.93 pmol/l) concentrations, and the highest prevalence rate (52.94%) for low T3 syndrome among the three subgroups ( Table 3) .
As demonstrated in Supporting Information, Table 3 , we conducted the univariate and multivariate logistic regression analyses to screen the independent variables associated with short-term TTFT (with indication at diagnosis) and shortterm CSS (nonsurvivor with CSS 2 years). In the multivariate analyses of short-term CSS, low T3 syndrome showed significance in both complete (p 5 0.046) and PSM datasets (p 5 0.045). However, probably for the reason that low T3 syndrome was not a CLL treatment indicator, no 
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Abbreviations: 95% CI, 95% confidence interval; evident correlation was shown as to short-term TTFT (p 5 0.819 for complete dataset and p 5 0.738 for PSM dataset). The above findings may illustrate the impact of low T3 syndrome in short-term progression and disease-related death.
Concurrently low FT3, FT4 and TSH predict worst survival in patients with low T3 syndrome Thirty-seven (14.34%) patients were diagnosed with low T3 syndrome at first hospital admission for CLL. All these patients received chemotherapies and 21 (56.76%) of them died. We noticed that CSS status in patients with low T3 syndrome was dependent on serum FT4 concentration. Mean FT4 levels in alive subjects (15.08 6 3.34 pmol/l) were significantly higher compared to those in deceased subjects (9.83 6 2.69 pmol/l) (p < 0.001). Figure 2 showed the survival curves of patients with low T3 syndrome stratified by FT3, FT4 and TSH levels. Subjects with synchronously low FT3 and FT4 were more likely to have worse TTFT and CSS than those with only low FT3 (p 5 0.029 for TTFT and p < 0.001 for CSS). We further subdivided the patients with synchronously low FT3 and FT4 into two groups based on TSH level. Interestingly, subjects with synchronously low FT3, FT4 and TSH had poorer CSS than those with only low FT3 and FT4 (p 5 0.001), while no significance was found as to TTFT (p 5 0.700). These findings might imply that FT4 and TSH concentrations could further identify high-risk cases in CLL patients with low T3 syndrome.
Low T3 syndrome improves the risk stratification of CLL-IPI
ROC curves were constructed to analyze the ability of serum FT3, FT4 and TSH in predicting TTFT and CSS of CLL patients. The AUCs of FT3 were 0.701 (95% CI: 0.641-0.757) for TTFT and 0.729 (95% CI: 0.670-0.783) for CSS, which were both superior to those of FT4 and TSH. The best cutoff points with the maximum Youden index for TTFT and CSS were FT3 3.77 and 3.72 pmol/l, respectively. Given that low T3 syndrome, together with the other five parameters which are also included in CLL-IPI (TP53 status, IGHV mutational status, b 2 -MG concentration, Binet stage and age), was the independent prognostic factor for CSS in the multivariate analyses, combination of low T3 syndrome and CLL-IPI might improve the prognostic capacity of CLL-IPI. We discovered that low T3 syndrome as one additional point to CLL-IPI obtained significantly larger AUCs both in TTFT and CSS prediction than CLL-IPI alone (ROC 0.775 vs 0.763, p < 0.001 for TTFT; ROC 0.826 vs 0.816, p 5 0.031 for CSS), while low T3 syndrome as two additional points demonstrated no significance in CSS prediction (p 5 0.069). Thus, a novel Prognostic Index (CLL-PI) was generated by the sum of CLL-IPI and one point for the presence of low T3 syndrome (Figs. 3a and 3b) .
Further validation of CLL-PI was conducted by segregating the CLL cohort into four risk grades: low-risk group (CLL-PI 0 2 2), intermediate-risk group (CLL-PI 3-5), highrisk group (CLL-PI 6-8) and very-high-risk group (CLL-PI 9-11). The immediate treatment and 3-year TTFT, 3-year and 5-year CSS of the entire cohort stratified by CLL-IPI and CLL-PI were demonstrated in Supporting Information, Table 4 . CLL-PI widened the definition of very-high-risk patients especially for CSS, and maintained equivalent accuracy to CLL-IPI in low-risk patients. Pairwise comparisons for CLL-PI demonstrated a significant difference in CSS between every two specific groups (Supporting Information, Table 5 ). However, as for CLL-IPI, no significant difference in CSS was identified between intermediate-and high-risk groups (p 5 0.297) (Supporting Information, Table 6 ). These results suggested that CLL-PI could accurately differentiate prognosis and improve the risk stratification of CLL-IPI (Figs.3c-3f ).
Discussion
Low thyroid hormone concentrations, in particular, low serum FT3 concentration, have been well-described to be associated with prognosis in severe nonthyroidal illness, including cardiovascular disease and chronic kidney disease. To our knowledge, this is the first study providing evidence of low T3 syndrome as a strong predictive marker for adverse prognosis in CLL survival. Although the pathophysiologic correlation between low T3 syndrome and malignancies is not fully elucidated, thyroid hormone profile as a simple and easily measured parameter may be a good candidate for predicting prognosis in future clinical practice of CLL.
In the last two decades, low T3 syndrome or low T3 state was reported to be highly prevalent in critically ill patients, with the incidence rate of 90.0% in severe trauma, 4 78.6% in end-stage renal disease, 28 56.6% in acute stroke, 29 53.1% in respiratory failure, 9 31.8% in community-acquired pneumonia 30 and 30.2% in heart disease. 5 For the presence of low T3 syndrome in malignancies, Bunevicius et al. reported that 74% of patients with brain tumor had low T3 syndrome. 10 Yasar et al. observed a 44.9% incidence in small-cell lung cancer and 42.3% in non-small-cell lung cancer. 12 The prevalence of low T3 syndrome in breast cancer patients at initial diagnosis (16.5%) was also higher than that in breast benign lesions (7.3%). 31 Among 258 CLL patients enrolled in our study, only 37 (14.34%) had low T3 syndrome at first admission, which was evidently less than the previous findings, but basically in concordance with our previous study on DLBCL (12.77%). 14 As for baseline characteristics, we noticed that parameters of CLL severity were correlated with low T3 syndrome and serum FT3 concentration. Similar to our results, Caregaro et al. found that the frequency of low T3 syndrome in cirrhotic patients was positively related to child classification defining severity of cirrhosis, 32 and Pfister et al. indicated that increasing severity of cardiac dysfunction went along with advancing derangement in thyroid function. 33 As for malignancies, lower FT3 concentration in brain tumor patients was shown to be associated with worse emotional and physical aspects of health-related quality of life (HRQoL), poorer functional and cognitive status and severer discharge outcome. 10, 11 Moreover, a positive association between the magnitude of thyroid hormone reduction and severity of lung cancer was also generally discussed. 12 In consensus with our findings on a panel of laboratorial data, Fan et al. described that serum T3 was positively correlated with anemia (Hb) and protein-energy nutrition (serum albumin), and negatively related to inflammation (CRP), 8 suggesting associations among low T3 syndrome, malnutritioninflammation complex syndrome and anemia.
Previous epidemiological studies demonstrated that low T3 syndrome was an independent prognostic predictor of poor survival in severe burn, 34 sepsis, 3 acute cerebrovascular disorders, 6 chronic heart failure 35 and respiratory failure, 9 end-stage renal disease 36 and hemodialysis patients. 37 However, the role of low T3 syndrome in cancer prognosis has only been well-analyzed in primary brain tumor and lung cancer, manifesting that low T3 syndrome can serve as a predictor of unfavorable clinical outcome in glioma, small-cell lung cancer and non-small-cell lung cancer, rather than as an innocent bystander. 10, 12, 13 We demonstrated in our study that low T3 syndrome was an independent risk factor not only for TTFT but also for CSS. We also discovered that patients with synchronously low FT3, FT4 and TSH had the worst survival. Proinflammatory cytokines were probably responsible for the decreased release of hypothalamic thyrotropin-releasing hormone in severe cases of low T3 syndrome, but without the deficiencies of other pituitary hormones such as adrenocorticotropic hormone and growth hormone. 38 In consistent with the above results, our center also reported a significant correlation between low T3 syndrome and poor prognosis in DLBCL.
14 For the reason that biological mechanisms underlying the association remain elusive, low T3 state could be interpreted just as a risk factor of increased mortality, and not as a direct causal factor contributing to the inferior prognosis in CLL.
We noticed that low T3 syndrome together with CLL-IPI (CLL-PI) had larger AUCs compared with CLL-IPI alone in TTFT and CSS prediction. Although statistically significant, the inclusion of low T3 syndrome only resulted in minor improvement. To interpret our results more cautiously, CLL-PI was not intended to replace CLL-IPI in clinical practice, but thyroid hormone dysfunction should be well-assessed and managed in CLL patient care. Our results remain to be replicated and confirmed in epidemiologic studies with larger samples, longer follow-up periods and full adjustments for covariates.
The pathogenetic mechanisms of this thyroid hormone derangement could be partially explained by central hypothyroidism, alterations in hormone binding, modified entry of thyroid hormone into tissue, changes in expression of iodothyronine deiodinases and thyroid hormone receptor. During acute critical illness, low T3 syndrome can be identified as an adaptive mechanism to preserve energy, reduce metabolic demand and thus appears to be beneficial. However, low T3 syndrome might turn disadvantageous with hypercatabolic response when critical illness enters a chronic phase. For instance, changes of thyroid hormone metabolism in muscle might be relevant for pathogenesis of myopathy associated with prolonged ventilator dependence 39 ; persistently low T3 may represent a maladaptive mechanism favoring morphostructural and functional cardiac remodeling, which might have an active role in pathogenesis of chronic heart failure. 40 For prolonged and consuming disease like CLL, mechanistic links could be multifactorial and bidirectional, including inflammation, protein malnutrition and anemia. Several inflammatory cytokines, such as tumor necrosis factor (TNF)-a, interleukin (IL)-1 and IL-6, inhibit the expression of type 1 5 0 -deiodinase which is responsible for peripheral conversion of T4 to T3, resulting in decreased T3 production. 41 These cytokines were also reported to be related with poor prognosis in CLL. 42, 43 Nutritional insufficiencies, fasting and calorie limitation as results of appetite loss in CLL may also be the putative mediators in low T3 syndrome development to lower energy expenditure. Moreover, the effects of thyroid hormones on hematopoiesis have been documented, such as an increase in production of erythropoietin and hematopoietic factors by nonerythroid cells. Low T3 syndrome could engender anemia, further leading to poor prognosis in CLL.
Although potentially promising, the usefulness of thyroid hormone administration as a new therapeutic strategy for low T3 syndrome is still debated. Pappa et al. claimed that the efficacy of thyroxine supplementation needed further validation in well-designed clinical research, 44 while De Groot et al. considered that low T3 syndrome as a manifestation of hypothalamic-pituitary dysfunction should be properly treated with replacement therapies. 45 Preclinical studies of several animal models proved that long-term T3 treatment could preserve mitochondria and prevent ischemic cardiac remodeling. 46, 47 Whereas some beneficial effects were observed in patients with heart failure, 48 exogenous thyroid hormone replacement may exacerbate energy wasting and protein degradation in dialysis patients with chronic kidney disease. 49 Although the use of exogenous T3 replacement in low T3 syndrome is controversial, interventional studies investigating whether normalization of T3 value could improve CLL survival may allow us to better discern the causal implication of low T3 syndrome in CLL.
The limitations of our study were illustrated as follows: the restriction within one institution; limited number of patients enrolled; thyroid hormone function was examined at a single point in time and analyses did not account for timevarying FT3 or FT4 levels.
In conclusion, low T3 syndrome was correlated with worse TTFT and CSS in CLL patients, and it was an independent prognostic factor for TTFT and CSS. Patients with synchronously low FT3, FT4 and TSH had the worst survival, and FT4 and TSH concentrations could further identify high risk cases in CLL patients with low T3 syndrome. Adding the criterion of low T3 syndrome could improve the prognostic capacity of CLL-IPI both in TTFT and CSS prediction. Thyroid hormone levels present high reproducibility and they can be easily measured in all diagnostic laboratories. Future rigorous longitudinal studies with larger samples and longer follow-up periods would allow us to disentangle the role of low T3 syndrome as a metabolic adaptation, marker of critical illness or predictor of inferior prognosis in the CLL population.
